Nautilus Biotechnology (NasdaqGS:NAUT) FY Conference March 02, 2026 10:30 AM ET Company ParticipantsSujal Patel - Co-Founder and CEOConference Call ParticipantsDan Brennan - Life Science Tools and Diagnostics AnalystDan BrennanGood morning. Dan Brennan, TD Cowen Life Science Tools and Diagnostics Analyst. Day one of the 46th annual TD Cowen Healthcare Conference. Pleased to be joined here on the stage with Co-founder and CEO of Nautilus, Sujal Patel. Sujal, welcome and thank you.Sujal PatelThanks, Dan, and ...

Group 1 - The market regulatory authority has achieved significant breakthroughs in the development of multi-dimensional detection technology and standard substances for characteristic biomolecules, addressing common international challenges in digital PCR and complex protein quantification [1] - A new method, ES-DMA-CPC, has been developed for the quantification of large molecular proteins up to 300kD without the need for enzymatic or hydrolytic processes, achieving equivalence with isotope dilution mass spectrometry [1] - The research team has created a series of standard substances, including DNA, viral nucleic acids, and monoclonal antibodies, which provide traceability benchmarks for PCR, digital PCR, sequencing, and mass spectrometry detection technologies [1] Group 2 - In the field of proteomics, a multi-level quality control and evaluation system has been established, along with a standard reference dataset that is internationally comparable and traceable [2] - An automated and intelligent model for quality assessment and anomaly detection in proteomics data has been developed, utilizing 10 machine learning algorithms and 170 hyperparameters, establishing a reliable data processing paradigm for large-scale proteomics research [2] - The research team has created the iDIA-QC tool for DIA-MS, marking a significant advancement in quality governance and methodological standardization in large-scale proteomics [2] Group 3 - High-performance AI models such as TSARseqNovo and GraphNet have been developed to achieve full-process automation in spectrum analysis, quality control, and standard comparison, laying the foundation for credible high-throughput omics data measurement [3] - A smart diagnostic system for the malignancy of thyroid nodules has been developed, achieving an accuracy rate of over 90%, utilizing targeted proteomics and AQUA technology for quantifiable and scalable screening of major diseases [3] - The series of original technologies significantly enhances the standardization of proteomics and diagnostics in China, strengthening the core competitiveness of the biopharmaceutical industry and promoting the development of precision medicine and public health emergency capabilities [3]

Bruker (NasdaqGS:BRKR) Q4 2025 Earnings call February 12, 2026 08:30 AM ET Speaker8Good morning, everyone, and welcome to the Bruker Corporation fourth quarter 2025 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one using a touchtone telephone. To withdr ...

编辑丨王多鱼 排版丨水成文 大脑 通过各专门区域之间的协调互动来指挥诸如认知、感觉和行动等复杂行为。人类拥有约 860 亿个皮层神经元和数量相近的神经胶质细胞，这两者与认知能力 呈正相关。 除了神经元和神经胶质细胞数量上的差异外，大脑区域的功能特化还源于其独特的分子结构，包括特定区域的神经递质系统、突触蛋白组合以及代谢特征。尽管 我们在人类大脑转录组图谱方面已取得进展，但基于大脑区域蛋白质表达的大脑功能区特征及其相互作用的研究，仍然有限。 2026 年 2 月 4 日，中国医学科学院北京协和医院 冷泠 研究员团队联合 陆军军医大学第一附属医院（西南医院） 卞修武 院士、 北京蛋白质组研究中心 朱云平 研究员 ，在 Signal Transduction and Targeted Therapy 期刊发表了题为： Region-resolved proteomic map of the human brain: functional interconnections and neurological implications 的研究论文。 该研究绘制了 人类大脑不同区域的蛋白质组图谱 ，以探究 不同脑区之间的功 ...

Core Insights - The recent conference in Guangzhou revealed significant findings regarding aging and its biological connections to chronic diseases, emphasizing the potential for targeted interventions in aging processes [1][3]. Group 1: Research Findings - Professor Deng Haiteng from Tsinghua University reported a breakthrough in proteomics, identifying a significant increase in the "immunoglobulin profile" in multiple organs of aging mice, indicating immune system dysregulation as a core biological feature of aging [1][3]. - The research discovered plasma protein biomarkers that can predict biological age and key intervention targets, providing new evidence for proactive health intervention strategies aimed at aging [3][6]. Group 2: Implications for Health Interventions - The findings suggest that aging itself can be a target for intervention rather than a passive outcome, offering a new scientific approach to prevent chronic diseases through anti-aging strategies [3][6]. - Researcher Huo Junsheng highlighted the shift in understanding aging from a vague concept of "damage accumulation" to precise "identification dimensions," with over ten aging markers identified, including telomere shortening and mitochondrial dysfunction, which provide clear targets for product development [6][8].

Bio-Techne FY Conference Summary Company Overview - **Company**: Bio-Techne (NasdaqGS: TECH) - **Industry**: Life Sciences Tools - **Established**: 50 years ago - **Core Products**: 7,000 proteins and 400,000 antibodies, serving as foundational components for life science research tools [2][4] Key Business Areas 1. **Cell Therapy**: Focus on growing immune and regenerative cells to treat diseases [2][3] 2. **Proteomics**: Emphasis on proteomic analysis, with a belief in market growth potential [3][4] 3. **Spatial Biology**: Investigating tissue interactions to assess therapy effectiveness [3][4] 4. **Molecular Diagnostics**: Capable of analyzing difficult-to-read genes, addressing gaps in next-generation sequencing (NGS) [3][4] Recent Financial Performance - **Q1 2026 Results**: - Cell therapy business showed rapid growth, with 60% and 90% growth in previous quarters [5] - Two major customers received FDA Fast Track approval, leading to expected revenue boosts [5][22] - Large pharma customers continued double-digit growth for three consecutive quarters [6] - China market showed positive growth for two consecutive quarters [6] - Margins improved to 29.9%, exceeding the forecast of 20% [6] Market Insights - **Biopharma Market**: - Accounts for 50% of revenue; large pharma contributes 30% of that [8] - Large pharma showed resilience despite tariff concerns, while biotech funding declined mid-teens year-over-year [8][9] - Recent M&A activity and lower interest rates are expected to stabilize biotech funding [9] - **Academic Research Market**: - Represents 20% of revenue; U.S. academic research is 12% and Europe is 8% [10] - U.S. market faced turbulence due to budget cuts and funding shifts, but bipartisan support is anticipated [11] - Shift in funding focus from infectious diseases to neurology, oncology, and weight management [11][12] - **China Market**: - Historically significant growth driver, currently at 8% of revenue [14] - Increased sensitivity towards life sciences post-COVID, with a focus on novel modalities [15] - Expected growth in the mid-teens as activity levels improve [16] Product Innovations - **R&D Investment**: Over 8% of revenues reinvested into R&D [17] - **Key Innovations**: - AI-enhanced protein design for improved stability and sensitivity [17] - ProPak for cell therapy, reducing contamination risks [18] - Leo protein analysis instrument for high-volume testing [18] - Multi-omics method for spatial biology [19] - ESR1 breast cancer test for treatment resistance [20] Strategic Acquisitions - **Wilson Wolf**: Bio-Techne plans to acquire the remaining 80% of Wilson Wolf by 2027, enhancing its cell therapy capabilities [24][25] Market Outlook - **Fiscal 2026 Expectations**: - Anticipated single-digit growth, with potential for double-digit growth in normalized market conditions [28][29] - Recovery expected in biotech and academic markets, with stabilization in large pharma [30][31] - Continued market share gains anticipated in protein analytics and spatial biology [32] Conclusion - Bio-Techne is positioned for growth through strategic innovations, market recovery, and a focus on high-demand areas within the life sciences sector. The company is optimistic about future performance as market conditions stabilize and improve.

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $552,000, impacted by capital sales headwinds in the market [4][16] - Gross profit was $194,000, with a gross margin of 35% [16] - For the nine months ended September 30, 2025, revenue was $2.0 million, and gross profit was $1.0 million, with a gross margin of 52% [16][18] - Total operating expenses for Q3 2025 were $40 million, compared to $28.5 million in Q3 2024 [18] - Adjusted operating expenses for Q3 2025 were $21.4 million, down from $26.0 million in Q3 2024 [18] Business Line Data and Key Metrics Changes - The company launched an expanded set of instrument acquisition options, resulting in 12 new customers implementing the platform [5] - More than half of the new customers are in academic labs, a segment previously difficult to access due to NIH funding challenges [5] Market Data and Key Metrics Changes - The company experienced year-over-year revenue impacts due to capital market headwinds and NIH funding uncertainties [17] - The placements program has allowed access to key academic centers, with over half of placements going into academic labs [34] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength [4] - The Proteus platform is a key focus, with successful sequencing runs completed on prototype systems [9] - The company is exploring partnership opportunities to enhance development activities and expand market participation [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about early traction with the placement program despite ongoing capital market challenges [13] - The company anticipates modest improvement in Q4 2025, but not a significant upswing compared to historical trends [40] - There is uncertainty regarding NIH funding due to the government shutdown, but proposals indicate a potential retention of funding levels [41][42] Other Important Information - The company has a strong balance sheet with $230.5 million in cash and investments as of September 30, 2025 [20] - A Form S-3 shelf registration statement for $300 million was filed to support business initiatives [22] - Management and board collectively hold approximately 18% of the total outstanding stock, indicating strong investment in the company's success [24] Q&A Session Summary Question: Updates on the investor day and Proteus sequencer development - The investor day on November 19 will provide updates on Proteus, including early sequencing data and key milestones for 2026 [28][29] Question: Involvement in DARPA's PRESS program - The company is aware of the PRESS program but does not align perfectly with its microsystem strategy [31] Question: Breakdown of placements by market segment - More than half of the placements went into academic labs, with the remainder split between pharma, biotech, and agricultural testing [34] Question: Seasonal trends from Q3 to Q4 - A modest improvement is expected in Q4 2025, but not as significant as in typical years due to various challenges [40] Question: Key hurdles to market launch of Proteus - Key hurdles include scaling from prototypes to fully integrated systems and optimizing the platform for manufacturing [44][46]

Core Viewpoint - The article discusses a groundbreaking study on protein restriction (PR) and its potential anti-aging effects, highlighting the importance of dietary interventions in extending lifespan and improving health [1][2][12]. Group 1: Research Findings - The study systematically mapped the proteomic landscape of aging across 41 organs/tissues in male mice, revealing significant protein expression heterogeneity during aging [4]. - Protein restriction was found to significantly alleviate age-related protein expression abnormalities in various tissues [6]. - The research indicated that protein restriction reduces age-related DNA methylation accumulation and reverses abnormal protein phosphorylation patterns in aging tissues [6]. Group 2: Health Implications - The study confirmed that protein restriction has cross-species cardiovascular protective effects, supported by analyses of plasma samples from both mice and humans [7]. - It was noted that lower protein intake is associated with enhanced cardiovascular health and reduced inflammation risk in humans [11]. Group 3: Timing and Gender Differences - The effects of protein restriction vary by gender and timing, with middle age identified as the optimal period for dietary intervention [8][11].

Summary of the Conference Call for 诺禾致源 (Nuohe Zhiyuan) Company Overview - **Company**: 诺禾致源 (Nuohe Zhiyuan) - **Period**: January to September 2025 Key Financial Metrics - **Total Revenue**: 15.81 billion CNY, up 4.05% year-on-year [2][3] - **Q3 Revenue**: 5.41 billion CNY, up 3.47% year-on-year [3] - **Overseas Revenue**: 7.92 billion CNY, up 4.1% year-on-year, accounting for 50.09% of total revenue [2][3] - **Q3 Overseas Revenue**: 2.58 billion CNY, down 0.48% year-on-year [3] - **Domestic Revenue**: 7.89 billion CNY, up 4% year-on-year [2] - **Q3 Domestic Revenue**: 2.82 billion CNY, up 7.37% year-on-year, and up 8.61% quarter-on-quarter [5] - **Gross Margin**: 41.9%, down 0.7 percentage points year-on-year [10] - **Net Profit**: 1.16 billion CNY, down 10.17% year-on-year, with a net profit margin of 7.31% [11] - **R&D Investment**: 56.1 million CNY in Q3, focusing on emerging fields [12] Revenue Breakdown by Market - **Americas**: Q3 revenue down 12% due to changes in research funding and policy impacts [4] - **EMEA**: Q3 revenue down 12%, affected by project completion and funding transitions [4] - **Europe**: Q3 revenue up 19%, indicating strong performance [4] - **Customer Segmentation**: 70% of revenue from universities and research institutions, 30% from hospitals and enterprises [6] Product and Service Performance - **Life Sciences Research Services**: Revenue of 5.52 billion CNY, up 6.21% year-on-year [7] - **Monitoring and Sequencing Platform Services**: Revenue of 7.7 billion CNY, up 3.23% year-on-year, but Q3 revenue down 3.42% [7] - **Emerging Business Contributions**: Approximately 32% of total revenue, up 4 percentage points year-on-year, with a growth of about 20% [8] R&D and Innovation - **R&D Focus Areas**: Single-cell genomics, spatial genomics, proteomics, metabolomics, epigenetics, and long-read sequencing [12][18] - **AI Integration**: Progress in AI applications, particularly in omics data analysis and virtual cell modeling [20][28] Market Challenges and Strategies - **Domestic Market Competition**: Increased competition leading to a 30% price drop; company aims to reduce competition through mergers and acquisitions [16][23] - **Geopolitical Impact**: U.S. market affected by geopolitical tensions, but the company maintains strong relationships in key regions [21] - **Cash Flow Management**: Operating cash flow was negative 87 million CNY for the first nine months, but turned positive in Q3 at 77 million CNY [14] Future Outlook - **Expansion Plans**: Continued investment in overseas markets, including new laboratories in Singapore and Europe [30] - **Focus on NGS and AI**: Anticipated growth in NGS applications and AI integration to enhance research capabilities [24][28] Additional Insights - **Customer Base Growth**: Stable customer structure with a slight increase in contributions from universities and research institutions [6] - **Cash Flow Volatility**: Short-term fluctuations in cash flow due to proactive risk management strategies [14] - **Regulatory Environment**: Ongoing adjustments to align with changing policies in the domestic and international markets [26][27]

Core Insights - The π-HuB Park industrial park has been established in Guangzhou as a key component of the international scientific initiative π-HuB, marking a new phase of industrial collaboration and ecological development in the field of proteomics [1][4][9] - The π-HuB initiative aims to create a comprehensive "real-time panorama" of the proteome, facilitating advancements in biomedicine, clinical diagnostics, and agricultural biotechnology [2][3] - The establishment of the industrial park is expected to enhance Guangzhou's competitiveness in the global biomedicine sector and help capture opportunities in the trillion-dollar precision medicine market [9][10] Industry Overview - The global proteomics market is projected to grow at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2029, indicating significant investment and interest from major international players [3] - The π-HuB initiative has garnered support from over 114 top scientific teams across more than 20 countries and regions, highlighting its international collaboration and significance [2] Strategic Collaborations - The industrial park has formed strategic partnerships with leading companies such as Danaher, Thermo Fisher Scientific, and Dary Biotech, which will facilitate the development and commercialization of innovative technologies and products [1][9] - π-HuB will collaborate with Danaher to establish a joint innovation center aimed at nurturing and investing in high-potential early-stage projects [8] Regional Advantages - Guangzhou's strong medical and industrial foundation, including over 7,000 healthcare institutions and nearly 7,000 biopharmaceutical companies, positions it as a key player in the proteomics field [6] - The local government is providing comprehensive support in terms of platform development, talent acquisition, clinical resources, and financial backing to facilitate the growth of the π-HuB initiative [6] Future Prospects - The establishment of the π-HuB Park is expected to attract more scientists and entrepreneurs to Guangzhou, fostering the growth of leading companies in the proteomics industry and transforming technological advantages into industrial strengths [10]